Sangamo Therapeutics

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sangamo Therapeutics excels in 2022 trials, prioritizes innovative programs

Sangamo Therapeutics had a strong year in 2022, focusing on key programs like CAR-Treg and Fabry disease while making strategic decisions to optimize resources.
Positive trial results and FDA alignment signal progress and potential for future collaborations and advancements in treatments.
Challenges include resource reallocation, endpoint validation, and data transparency, which require careful management and strategic planning.
Overall, Sangamo's performance, strengths, and opportunities position the company well for continued growth and innovation in the biopharmaceutical sector.

Sangamo Therapeutics reports strong Q1 revenue and strategic reorganization

Sangamo Therapeutics is strategically reorganizing to focus on neurology, Fabry, and TX200 CAR-Treg programs, aiming to reduce cash burn and enhance operational efficiency.
The company's emphasis on genomic medicines for chronic pain and neurological disorders highlights its commitment to addressing significant unmet medical needs.
While facing capital constraints, Sangamo is exploring financing options and partnerships to support future growth and innovation, balancing patient benefit and safety in clinical advancements.

Sangamo Therapeutics excels in clinical progress and strategic collaborations

Sangamo Therapeutics demonstrates strong performance in clinical and preclinical programs, backed by a solid financial position and strategic collaborations. Challenges include the need for additional funding and ensuring successful trial execution. Opportunities for growth through expanding partnerships and innovative genomic engineering approaches.

Sangamo shifts focus to neurology, eyes partnerships for growth

Sangamo's strategic shift to neurology shows promise but requires navigating challenges of restructuring and resource reallocation.
The company's financial discipline and focus on operational efficiency aim to ensure self-sustainability until Q3 2024 without additional capital raises.
Progress in innovative therapies like CAR-Tregs and AAV capsid evolution positions Sangamo well for advancements in genomic medicine for neurological disorders.
Exploration of partnerships and monetization opportunities present avenues for growth and strategic advancement in Sangamo's therapeutic programs.

Sangamo Therapeutics excels in neurology advancements and financial stability

Sangamo Therapeutics made significant strides in neurology programs, financial stability, and technology advancements, positioning the company for future growth
Challenges in clinical trial navigation and funding require strategic planning, while opportunities in collaborations and partnerships offer avenues for expansion
Overall, Sangamo's focus on innovation, cost efficiency, and strategic collaborations bode well for its continued success in the neurology and gene therapy space

Sangamo Therapeutics reports positive trial results and lucrative collaborations

Sangamo Therapeutics showcased strong performance in their pipeline with positive trial results and progress in the Fabry disease program.
The company's collaboration agreements and innovative technologies position them well for future growth and revenue generation.
While facing challenges in manufacturing and commercialization, Sangamo has significant opportunities in advancing genomic medicines and expanding therapeutic applications.

Sangamo Therapeutics excels in Q3, secures key partnerships and milestones

Sangamo Therapeutics demonstrated strong performance in Q3 2024, with notable advancements in key programs and financial stability.
The company's strategic partnerships, licensing agreements, and regulatory progress position it well for future growth and commercial success.
While facing funding challenges and regulatory timelines, Sangamo has opportunities to expand its pipeline, address unmet medical needs, and drive innovation in the biopharmaceutical space.
Overall, Sangamo's progress in multiple programs and ongoing discussions for collaborations underscore its commitment to delivering innovative therapies to patients in need.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Sangamo Therapeutics (SGMO) Stock?

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Vertex Pharmaceuticals

In the Century of Biology, it pays to own the future of curing disease at the root.

CRISPR Gene Editing: Owning the Future of Medicine

Pfizer

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525 or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. These data are being presented today at the 62nd American Society for Hematology Annual meeting taking place virtually from December 5th - 8th. The oral pres

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy

Gene regulation targeted at RNA or DNA has enormous potential for previously intractable nervous system disorders. Allele-specific gene regulation is a more precise approach targeting only the mutant gene tied to diseases such as ALS and Huntington's.

Genomic Medicine: Slowly Moving To All At Once

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2020 Results - Earnings Call Transcript

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights. “We are pleased with the clinical execution momentum across our portfolio, including the first patient dosed in the registrational AFFINE study of our investigational hemophilia A gene therapy partnered with Pfizer, as well as dosing of the first two patients in the Phase 1/2 STAAR study evaluating our Fabry

Sangamo Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2020 financial results after the market closes on Wednesday, November 4, 2020. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business update

Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Sangamo Therapeutics (SGMO) Report Negative Q3 Earnings? What You Should Know

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in patients with modera

Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment

Sangamo Therapeutic, Inc. (NASDAQ: SGMO) is a clinical-stage biotech focused on genomic medicines using proprietary platform technologies covering gene therapy, ex-vivo gene-edited cell therapy, and in-vivo genome editing/regulation.

Sangamo: $665M In Cash Ready To Be Deployed Across A Pipeline Of 18 Therapeutics And 2 New 2020 Partnerships, 29% Upside

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc.

Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors

A Relative Strength Rating upgrade for Sangamo Therapeutics shows improving technical performance. Will it continue?

Sangamo Therapeutics Getting Closer To Key Technical Benchmark

Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?

CRISPR Stocks: Buy or Trade?

A Relative Strength Rating upgrade for Sangamo Therapeutics shows improving technical performance.
The post Stocks With Rising Relative Price Strength: Sangamo Therapeutics appeared first on Investor's Business Daily.

Stocks With Rising Relative Price Strength: Sangamo Therapeutics

Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2020 Results - Earnings Call Transcript

Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results

Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

Sangamo Therapeutics Announces Second Quarter 2020 Conference Call and Webcast

Sangamo Therapeutics (SGMO) Earnings Expected to Grow: Should You Buy?

The Biogen collaboration was completed in 2Q.  Cash is now expected to fund operations beyond BLA timing for Hemophilia A.

Sangamo H2 2020 Preview

Moderna

These three stocks are positioned for growth -- but investors must tread carefully in the short term.

3 Top Biotech Stocks to Watch in July

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization. Going forward, research and development will each be managed as separate functions. A search for a Head of Development is underway. Jason Fontenot, Senior Vice President, Cell Therapy, will assume the role of Interim Head of Research. The heads of research and development will report to CEO Sandy Macrae. “The changes we are announcing today are desig

Sangamo Announces R&D Organization Changes

While the data looks good so far, the duo's treatment is behind a similar BioMarin therapy in the testing and approval process.

Pfizer and Sangamo's Gene Therapy Continues to Help Patients with Hemophilia in Clinical Trial

Investors need to pay close attention to Sangamo (SGMO) stock based on the movements in the options market lately.

News for Sangamo Therapeutics Stock (SGMO)